{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:24Z","timestamp":1753891884466,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To elucidate the association between allergy history and response to immune checkpoint inhibition (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (RM\/HNSCC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients receiving ICI treatment for RM\/HNSCC were retrospectively enrolled and classified into two groups based on their previous allergy history. The primary outcome variable assessed was the response to ICI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 157 patients were included, of whom 27 reported a history of allergies. In multivariate analysis, patients with allergies exhibited an odds ratio of 2.78 [95% confidence interval: 1.54-5.99], significantly surpassing that of the non-allergic group. Other independent predictors of ICI benefit included current smoking status and the primary tumor site being in the oropharynx or hypopharynx. Neither progression-free survival nor overall survival was adversely affected by prior allergy history or smoking status or HPV status or PD-L1 expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A prior history of allergies is associated with an enhanced response to immunotherapy in patients with RM\/HNSCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1486583","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:05:47Z","timestamp":1742954747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Allergic history and responses to immunotherapy in individuals with recurrent or metastatic head and neck squamous cell carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Yannan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qizhe","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunshuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/all.16246","article-title":"Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper","volume":"79","author":"Pascal","year":"2024","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18110","DOI":"10.1038\/s41598-021-97200-y","article-title":"Clinical and immunological allergy assessment in cancer patients","volume":"11","author":"Carneiro","year":"2021","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03131","article-title":"Allergen-specific antibodies regulate secondary allergen-specific immune responses","volume":"9","author":"Eckl-Dorna","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0965","article-title":"Association between allergies and risk of pancreatic cancer","volume":"23","author":"Cotterchio","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1037884","article-title":"Review of biomarkers for response to immunotherapy in HNSCC microenvironment","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15006","DOI":"10.1038\/s41598-024-65051-y","article-title":"Allergies and risk of head and neck cancer: a case-control study","volume":"14","author":"Fekrazad","year":"2024","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055138","article-title":"Allergies and risk of head and neck cancer: an original study plus meta-analysis","volume":"8","author":"Hsiao","year":"2013","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000000710","article-title":"Squamous cell carcinoma of the oral cavity in ever smokers: a matched-pair analysis of survival","volume":"25","author":"Fang","year":"2014","journal-title":"J Craniofac Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701181","article-title":"Incidence and prognostic significance of PD-L1 expression in high-grade salivary gland carcinoma","volume":"11","author":"Fang","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00741","article-title":"Correlates of cetuximab efficacy in recurrent and metastatic head and neck squamous cell carcinoma previously treated with immunotherapy","volume":"9","author":"Park","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01902-6","article-title":"Interplay of IL-33 and IL-35 modulates th2\/th17 responses in cigarette smoke exposure HDM-induced asthma","volume":"47","author":"Liu","year":"2024","journal-title":"Inflammation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4110\/in.2024.24.e8","article-title":"Cytokines in follicular helper T cell biology in physiologic and pathologic conditions","volume":"24","author":"Choi","year":"2024","journal-title":"Immune Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1248327","article-title":"Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients","volume":"5","author":"Nonomura","year":"2016","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100875","DOI":"10.1016\/j.waojou.2024.100875","article-title":"Maternal smoking around birth and its influence on offspring allergic diseases: A mendelian randomization study","volume":"17","author":"Ruan","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13852","article-title":"Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study","volume":"12","author":"Cortellini","year":"2021","journal-title":"Thorac Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0007","article-title":"Smoking status-based efficacy difference in anti-PD-1\/PD-L1 immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Nie","year":"2020","journal-title":"Immunotherapy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ohn.v170.3","article-title":"Allergy history and immunotherapy response in patients with recurrent\/metastatic head and neck squamous cell carcinoma","volume":"170","author":"Alkhatib","year":"2024","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1760","article-title":"Tumor immunity and immunotherapy for HPV-related cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discovery"},{"key":"B25","doi-asserted-by":"publisher","first-page":"106363","DOI":"10.1016\/j.oraloncology.2023.106363","article-title":"The effect of opioids on the efficacy of immunotherapy in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"140","author":"Scheff","year":"2023","journal-title":"Oral Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1486583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T11:39:28Z","timestamp":1743680368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1486583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1486583"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1486583","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"1486583"}}